Host immune responses to the intracellular bacteria Brucella: Does the bacteria instruct the host to facilitate chronic infection?

Critical Reviews in Immunology

Volumn 26, Issue 5, 2006, Pages 407-442

  Baldwin, Cynthia L ^a   Goenka, Radhika ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Antibodies; Brucellosis; Cell mediated immunity; Macrophages; T cells; TLR

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; LIPID A; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL GENE; BACTERIAL VIRULENCE; BRUCELLA; BRUCELLOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GRAM NEGATIVE BACTERIUM; IMMUNE RESPONSE; INFECTION; INTERFERON PRODUCTION; NATURAL KILLER CELL; PHAGOCYTE; PRIORITY JOURNAL; REVIEW;

EID: 33751216465     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v26.i5.30     Document Type: Review

References (183)

1. Young EJ. Human brucellosis. Rev Infect Dis. 1983;5(5):821-42.
2. Ersoy Y, Sonmez E, Tevfik MR, But AD. Comparison of three different combination therapies in the treatment of human brucellosis. Trop Doct. 2005;35(4):210-2.
3. Rahman A, Burma O, Felek S, Yekeler H. Atrial septal defect presenting with Brucella endocarditis. Scand J Infect Dis. 2001;33(10):776-7.
4. Hoover DL, Nikolich MP, Izadjoo MJ, Borschel RH, Bhattacharjee AK. Development of new Brucella vaccines by molecular methods. In: Lopez-Goni I, Moriyon I, editors. Brucella molecular and cellular biology. Norfolk: Horizon Bioscience; 2004. p. 369-402.
5. Sacks D, Sher A. Evasion of innate immunity by parasitic protozoa. Nat Immunol. 2002;3(11):1041-7.
6. Anderson TD, Cheville NF. Ultrastructural morphometric analysis of Brucella abortus-infected trophoblasts in experimental placentitis. Bacterial replication occurs in rough endoplasmic reticulum. Am J Pathol. 1986;124(2):226-37.
7. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melian A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science. 1998;282(5386):121-5.
8. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136(7):2348-57.
9. Murphy EA, Sathiyaseelan J, Parent MA, Zou B, Baldwin CL. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology. 2001;103(4):511-8.
10. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164(12):6166-73.
11. Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003;73(2):209-12.
12. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388(6640):394-7.
13. Simms HH, Gaither TA, Fries LF, Frank MM. Monokines released during short-term Fc gamma receptor phagocytosis up-regulate polymorphonuclear leukocytes and monocyte-phagocytic function. J Immunol. 1991;147(1):265-72.
14. Debets JM, van de Winkel JG, Ceuppens JL, Dieteren IE, Buurman WA. Cross-linking of both Fc gamma RI and Fc gamma RII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-Fc gamma R interactions. Functional activation of Fc gamma RII by treatment with proteases or neuraminidase. J Immunol. 1990;144(4):1304-10.
15. Krutmann J, Kirnbauer R, Kock A, Schwarz T, Schopf E, May LT, Sehgal PB, Luger TA. Cross-linking Fc receptors on monocytes triggers IL-6 production. Role in anti-CD3-induced T cell activation. J Immunol. 1990;145(5):1337-42.
16. Anderson CF, Mosser DM. Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J Immunol. 2002;168(8):3697-701.
17. Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol. 2002;72(1):101-6.
18. Bosseray N, Plommet M. Brucella suis S2, Brucella melitensis Rev. 1 and Brucella abortus S19 living vaccines: residual virulence and immunity induced against three Brucella species challenge strains in mice. Vaccine. 1990;8(5):462-8.
19. Araya LN, Winter AJ. Comparative protection of mice against virulent and attenuated strains of Brucella abortus by passive transfer of immune T cells or serum. Infect Immun. 1990;58(1):254-6.
20. Ko J, Gendron-Fitzpatrick A, Splitter GA. Susceptibility of IFN regulatory factor-1 and IFN consensus sequence binding protein-deficient mice to brucellosis. J Immunol. 2002;168(5):2433-40.
21. Kohler S, Michaux-Charachon S, Porte F, Ramuz M, Liautard JP. What is the nature of the replicative niche of a stealthy bug named Brucella? Trends Microbiol. 2003;11(5):215-9.
22. Gorvel JP, Moreno E. Brucella intracellular life: from invasion to intracellular replication. Vet Microbiol. 2002;90(1-4):281-97.
23. Harmon BG, Adams LG, Frey M. Survival of rough and smooth strains of Brucella abortus in bovine mammary gland macrophages. Am J Vet Res. 1988;49(7):1092-7.
24. Pizarro-Cerda J, Moreno E, Sanguedolce V, Mege JL, Gorvel JP. Virulent Brucella abortus prevents lysosome fusion and is distributed within autophagosome-like compartments. Infect Immun. 1998;66(5):2387-92.
25. Porte F, Naroeni A, Ouahrani-Bettache S, Liautard JP. Role of the Brucella suis lipopolysaccharide O antigen in phagosomal genesis and in inhibition of phagosome-lysosome fusion in murine macrophages. Infect Immun. 2003;71(3):1481-90.
26. Jiang X, Baldwin CL. Effects of cytokines on intracellular growth of Brucella abortus. Infect Immun. 1993;61(1):124-34.
27. Jiang X, Leonard B, Benson R, Baldwin CL. Macrophage control of Brucella abortus: role of reactive oxygen intermediates and nitric oxide. Cell Immunol. 1993;151(2):309-19.
28. Baldwin CL, Jiang X, Fernandes DM. Macrophage control of Brucella abortus: influence of cytokines and iron. Trends Microbiol. 1993;1(3):99-104.
29. Caron E, Peyrard T, Kohler S, Cabane S, Liautard JP, Dornand J. Live Brucella spp. fail to induce tumor necrosis factor alpha excretion upon infection of U937-derived phagocytes. Infect Immun. 1994;62(12):5267-74.
30. Rittig MG, Alvarez-Martinez MT, Porte F, Liautard JP, Rouot B. Intracellular survival of Brucella spp. in human monocytes involves conventional uptake but special phagosomes. Infect Immun. 2001;69(6):3995-4006.
31. Drazek ES, Houng HS, Crawford RM, Hadfield TL, Hoover DL, Warren RL. Deletion of purE attenuates Brucella melitensis 16M for growth in human monocyte-derived macrophages. Infect Immun. 1995;63(9):3297-301.
32. Sathiyaseelan J, Jiang X, Baldwin CL. Growth of Brucella abortus in macrophages from resistant and susceptible mouse strains. Clin Exp Immunol. 2000;121(2):289-94.
33. Naroeni A, Porte F. Role of cholesterol and the ganglioside GM1 in entry and short-term survival of Brucella suis in murine macrophages. Infect Immun. 2002;70(3):1640-4.
34. Foulongne V, Bourg G, Cazevieille C, Michaux-Charachon S, O'Callaghan D. Identification of Brucella suis genes affecting intracellular survival in an in vitro human macrophage infection model by signature-tagged transposon mutagenesis. Infect Immun. 2000;68(3):1297-303.
35. Watarai M, Makino S, Fujii Y, Okamoto K, Shirahata T. Modulation of Brucella-induced macropinocytosis by lipid rafts mediates intracellular replication. Cell Microbiol. 2002;4(6):341-55.
36. Detilleux PG, Deyoe BL, Cheville NF. Entry and intracellular localization of Brucella spp. in Vero cells: fluorescence and electron microscopy. Vet Pathol. 1990;27(5):317-28.
37. Detilleux PG, Deyoe BL, Cheville NF. Penetration and intracellular growth of Brucella abortus in non-phagocytic cells in vitro. Infect Immun. 1990;58(7):2320-8.
38. Detilleux PG, Deyoe BL, Cheville NF. Effect of endocytic and metabolic inhibitors on the internalization and intracellular growth of Brucella abortus in Vero cells. Am J Vet Res. 1991;52(10):1658-64.
39. Pei J, Ficht TA. Brucella abortus rough mutants are cytopathic for macrophages in culture. Infect Immun. 2004;72(1):440-50.
40. Jimenez de Bagues MP, Terraza A, Gross A, Dornand J. Different responses of macrophages to smooth and rough Brucella spp.: relationship to virulence. Infect Immun. 2004;72(4):2429-33.
41. Fernandez-Prada CM, Zelazowska EB, Nikolich M, Hadfield TL, Roop RM, Robertson GL, Hoover DL. Interactions between Brucella melitensis and human phagocytes: bacterial surface O-polysaccharide inhibits phagocytosis, bacterial killing, and subsequent host cell apoptosis. Infect Immun. 2003;71(4):2110-9.
42. Watarai M, Makino SI, Michikawa M, Yanagisawa K, Murakami S, Shirahata T. Macrophage plasma membrane cholesterol contributes to Brucella abortus infection of mice. Infect Immun. 2002;70(9):4818-25.
43. Dermine JF, Duclos S, Garin J, St Louis F, Rea S, Parton RG, Desjardins M. Flotillin-1-enriched lipid raft domains accumulate on maturing phagosomes. J Biol Chem. 2001;276(21):18507-12.
44. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol. 2002;14(1):103-10.
45. Kim S, Watarai M, Suzuki H, Makino S, Kodama T, Shirahata T. Lipid raft microdomains mediate class A scavenger receptor-dependent infection of Brucella abortus. Microb Pathog. 2004;37(1):11-9.
46. Nigou J, Zelle-Rieser C, Gilleron M, Thurnher M, Puzo G. Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. J Immunol. 2001;166(12):7477-85.
47. Dolganiuc A, Bakis G, Kodys K, Mandrekar P, Szabo G. Acute ethanol treatment modulates Toll-like receptor-4 association with lipid rafts. Alcohol Clin Exp Res. 2006;30(1):76-85.
48. Watarai M, Kim S, Erdenebaatar J, Makino S, Horiuchi M, Shirahata T, Sakaguchi S, Katamine S. Cellular prion protein promotes Brucella infection into macrophages. J Exp Med. 2003;198(1):5-17.
49. Watarai M. Interaction between Brucella abortus and cellular prion protein in lipid raft microdomains. Microbes Infect. 2004;6(1):93-100.
50. Fontes P, Alvarez-Martinez MT, Gross A, Carnaud C, Kohler S, Liautard JP. Absence of evidence for the participation of the macrophage cellular prion protein in infection with Brucella suis. Infect Immun. 2005;73(10):6229-36.
51. Arellano-Reynoso B, Lapaque N, Salcedo S, Briones G, Ciocchini AE, Ugalde R, Moreno E, Moriyon I, Gorvel JP. Cyclic beta-1,2-glucan is a Brucella virulence factor required for intracellular survival. Nat Immunol. 2005;6(6):618-25.
52. Wright SD, Silverstein SC. Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes. J Exp Med. 1983;158(6):2016-23.
53. Eze MO, Yuan L, Crawford RM, Paranavitana CM, Hadfield TL, Bhattacharjee AK, Warren RL, Hoover DL. Effects of opsonization and gamma interferon on growth of Brucella melitensis 16M in mouse peritoneal macrophages in vitro. Infect Immun. 2000;68(1):257-63.
54. Liautard JP, Gross A, Dornand J, Kohler S. Interactions between professional phagocytes and Brucella spp. Microbiologia. 1996;12(2):197-206.
55. Elzer PH, Jacobson RH, Jones SM, Nielsen KH, Douglas JT, Winter AJ. Antibody-mediated protection against Brucella abortus in BALB/c mice at successive periods after infection: variation between virulent strain 2308 and attenuated vaccine strain 19. Immunology. 1994;82(4):651-8.
56. Jones SM, Winter AJ. Survival of virulent and attenuated strains of Brucella abortus in normal and gamma interferon-activated murine peritoneal macrophages. Infect Immun. 1992;60(7):3011-4.
57. Canning PC, Roth JA, Deyoe BL. Release of 5′-guanosine monophosphate and adenine by Brucella abortus and their role in the intracellular survival of the bacteria. J Infect Dis. 1986;154(3):464-70.
58. Sowa BA, Kelly KA, Ficht TA, Adams LG. Virulence associated proteins of Brucella abortus identified by paired two-dimensional gel electrophoretic comparisons of virulent, vaccine and LPS deficient strains. Appl Theor Electrophor. 1992;3(1):33-40.
59. Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science. 2004;304(5673):1014-8.
60. Doyle SE, O'Connell RM, Miranda GA, Vaidya SA, Chow EK, Liu PT, Suzuki S, Suzuki N, Modlin RL, Yeh WC, Lane TF, Cheng G. Toll-like receptors induce a phagocytic gene program through p38. J Exp Med. 2004;199(1):81-90.
61. Boschiroli ML, Ouahrani-Bettache S, Foulongne V, Michaux-Charachon S, Bourg G, Allardet-Servent A, Cazevieille C, Liautard JP, Ramuz M, O'Callaghan D. The Brucella suis virB operon is induced intracellularly in macrophages. Proc Natl Acad Sci U S A. 2002;99(3):1544-9.
62. den Hartigh AB, Sun YH, Sondervan D, Heuvelmans N, Reinders MO, Ficht TA, Tsolis RM. Differential requirements for VirB1 and VirB2 during Brucella abortus infection. Infect Immun. 2004;72(9):5143-9.
63. Sun YH, den Hartigh AB, Santos RL, Adams LG, Tsolis RM. virB-Mediated survival of Brucella abortus in mice and macrophages is independent of a functional inducible nitric oxide synthase or NADPH oxidase in macrophages. Infect Immun. 2002;70(9):4826-32.
64. Celli J, de Chastellier C, Franchini DM, Pizarro-Cerda J, Moreno E, Gorvel JP. Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J Exp Med. 2003;198(4):545-56.
65. Celli J, Salcedo SP, Gorvel JP. Brucella coopts the small GTPase Sar1 for intracellular replication. Proc Natl Acad Sci U S A. 2005;102(5):1673-8.
66. Gross A, Terraza A, Ouahrani-Bettache S, Liautard JP, Dornand J. In vitro Brucella suis infection prevents the programmed cell death of human monocytic cells. Infect Immun. 2000;68(1):342-51.
67. Galdiero E, Romano CC, Vitiello M, Nuzzo I, Del Vecchio E, Bentivoglio C, Perillo G, Galdiero F. HSP and apoptosis in leukocytes from infected or vaccinated animals by Brucella abortus. New Microbiol. 2000;23(3):271.
68. Tolomeo M, Di Carlo P, Abbadessa V, Titone L, Miceli S, Barbusca E, Cannizzo G, Mancuso S, Arista S, Scarlata F. Monocyte and lymphocyte apoptosis resistance in acute and chronic brucellosis and its possible implications in clinical management. Clin Infect Dis. 2003;36(12):1533-8.
69. Jiang X, Baldwin CL. Iron augments macrophage-mediated killing of Brucella abortus alone and in conjunction with interferon-gamma. Cell Immunol. 1993;148(2):397-407.
70. Ottones F, Liautard J, Gross A, Rabenoelina F, Liautard JP, Favero J. Activation of human Vgamma9 Vdelta2 T cells by a Brucella suis non-peptidic fraction impairs bacterial intracellular multiplication in monocytic infected cells. Immunology. 2000;100(2):252-8.
71. Leonard BA, Lopez-Goni I, Baldwin CL. Brucella abortus siderophore 2,3-dihydroxybenzoic acid protects Brucellae from killing by macrophages. Vet Res. 1997;28(1):87-92.
72. Bellaire BH, Elzer PH, Baldwin CL, Roop RM. Production of the siderophore 2,3-dihydroxybenzoic acid is required for wild-type growth of Brucella abortus in the presence of erythritol under low-iron conditions in vitro. Infect Immun. 2003;71(5):2927-32.
73. Parent MA, Bellaire BH, Murphy EA, Roop RM, Elzer PH, Baldwin CL. Brucella abortus siderophore 2,3-dihydroxybenzoic acid (DHBA) facilitates intracellular survival of the bacteria. Microb Pathog. 2002;32(5):239-48.
74. Gee JM, Valderas MW, Kovach ME, Grippe VK, Robertson GT, Ng WL, Richardson JM, Winkler ME, Roop RM. The Brucella abortus Cu,Zn superoxide dismutase is required for optimal resistance to oxidative killing by murine macrophages and wild-type virulence in experimentally infected mice. Infect Immun. 2005;73(5):2873-80.
75. Wang M, Qureshi N, Soeurt N, Splitter G. High levels of nitric oxide production decrease early but increase late survival of Brucella abortus in macrophages. Microb Pathog. 2001;31(5):221-30.
76. Gross A, Spiesser S, Terraza A, Rouot B, Caron E, Dornand J. Expression and bactericidal activity of nitric oxide synthase in Brucella suis-infected murine macrophages. Infect Immun. 1998;66(4):1309-16.
77. Lopez-Urrutia L, Alonso A, Nieto ML, Bayon Y, Orduna A, Sanchez CM. Lipopolysaccharides of Brucella abortus and Brucella melitensis induce nitric oxide synthesis in rat peritoneal macrophages. Infect Immun. 2000;68(3):1740-5.
78. Gross A, Bertholet S, Mauel J, Dornand J. Impairment of Brucella growth in human macrophagic cells that produce nitric oxide. Microb Pathog. 2004;36(2):75-82.
79. MacFarlane AS, Huang D, Schwacha MG, Meissler JJ Jr, Gaughan JP, Eisenstein TK. Nitric oxide mediates immunosuppression induced by Listeria monocytogenes infection: quantitative studies. Microb Pathog. 1998;25(5):267-77.
80. Loisel-Meyer S, Jimenez de Bagues MP, Basseres E, Dornand J, Kohler S, Liautard JP, Jubier-Maurin V. Requirement of norD for Brucella suis virulence in a murine model of in vitro and in vivo infection. Infect Immun. 2006;74(3):1973-6.
81. Blackwell JM, Barton CH, White JK, Roach TI, Shaw MA, Whitehead SH, Mock BA, Searle S, Williams H, Baker AM. Genetic regulation of leishmanial and mycobacterial infections: the Lsh/Ity/Bcg gene story continues. Immunol Lett. 1994;43(1-2):99-107.
82. Price RE, Templeton JW, Smith R III, Adams LG. Ability of mononuclear phagocytes from cattle naturally resistant or susceptible to brucellosis to control in vitro intracellular survival of Brucella abortus. Infect Immun. 1990;58(4):879-86.
83. Qureshi T, Templeton JW, Adams LG. Intracellular survival of Brucella abortus, Mycobacterium bovis BCG, Salmonella dublin, and Salmonella typhimurium in macrophages from cattle genetically resistant to Brucella abortus. Vet Immunol Immunopathol. 1996;50(1-2):55-65.
84. Feng J, Li Y, Hashad M, Schurr E, Gros P, Adams LG, Templeton JW. Bovine natural resistance associated macrophage protein 1 (Nramp1) gene. Genome Res. 1996;6(10):956-64.
85. Barthel R, Feng J, Piedrahita JA, McMurray DN, Templeton JW, Adams LG. Stable transfection of the bovine NRAMP1 gene into murine RAW264.7 cells: effect on Brucella abortus survival. Infect Immun. 2001;69(5):3110-9.
86. Guilloteau LA, Dornand J, Gross A, Olivier M, Cortade F, Vern YL, Kerboeuf D. Nramp1 is not a major determinant in the control of Brucella melitensis infection in mice. Infect Immun. 2003;71(2):621-8.
87. Mielke ME. T cell subsets in granulomatous inflammation and immunity to L. monocytogenes and B. abortus. Behring Inst Mitt. 1991;(88):99-111.
88. Zhan Y, Cheers C. Control of IL-12 and IFN-gamma production in response to live or dead bacteria by TNF and other factors. J Immunol. 1998;161(3):1447-53.
89. Araya LN, Elzer PH, Rowe GE, Enright FM, Winter AJ. Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J Immunol. 1989;143(10):3330-7.
90. Fernandes DM, Jiang X, Jung JH, Baldwin CL. Comparison of T cell cytokines in resistant and susceptible mice infected with virulent Brucella abortus strain 2308. FEMS Immunol Med Microbiol. 1996;16(3-4):193-203.
91. Huang LY, Aliberti J, Leifer CA, Segal DM, Sher A, Golenbock DT, Golding B. Heat-killed Brucella abortus induces TNF and IL-12p40 by distinct MyD88-dependent pathways: TNF, unlike IL-12p40 secretion, is Toll-like receptor 2 dependent. J Immunol. 2003;171(3):1441-6.
92. Duenas AI, Orduna A, Crespo MS, Garcia-Rodriguez C. Interaction of endotoxins with Toll-like receptor 4 correlates with their endotoxic potential and may explain the proinflammatory effect of Brucella spp. LPS. Int Immunol. 2004;16(10):1467-75.
93. Campos MA, Rosinha GM, Almeida IC, Salgueiro XS, Jarvis BW, Splitter GA, Qureshi N, Bruna-Romero O, Gazzinelli RT, Oliveira SC. Role of Toll-like receptor 4 in induction of cell-mediated immunity and resistance to Brucella abortus infection in mice. Infect Immun. 2004;72(1):176-86.
94. Giambartolomei GH, Zwerdling A, Cassataro J, Bruno L, Fossati CA, Philipp MT. Lipoproteins, not lipopolysaccharide, are the key mediators of the proinflammatory response elicited by heat-killed Brucella abortus. J Immunol. 2004;173(7):4635-42.
95. Huang LY, Ishii KJ, Akira S, Aliberti J, Golding B. Th1-like cytokine induction by heat-killed Brucella abortus is dependent on triggering of TLR9. J Immunol. 2005;175(6):3964-70.
96. Tibor A, Decelle B, Letesson JJ. Outer membrane proteins Omp10, Omp16, and Omp19 of Brucella spp. are lipoproteins. Infect Immun. 1999;67(9):4960-2.
97. Weiss DS, Takeda K, Akira S, Zychlinsky A, Moreno E. MyD88, but not toll-like receptors 4 and 2, is required for efficient clearance of Brucella abortus. Infect Immun. 2005;73(8):5137-43.
98. Netea MG, van Deuren M, Kullberg BJ, Cavaillon JM, Van der Meer JW. Does the shape of lipid A determine the interaction of LPS with Toll-like receptors? Trends Immunol. 2002;23(3):135-9.
99. Velasco J, Romero C, Lopez-Goni I, Leiva J, Diaz R, Moriyon I. Evaluation of the relatedness of Brucella spp. and Ochrobactrum anthropi and description of Ochrobactrum intermedium sp. nov., a new species with a closer relationship to Brucella spp. Int J Syst Bacteriol. 1998;48 Pt 3:759-68.
100. Velasco J, Bengoechea JA, Brandenburg K, Lindner B, Seydel U, Gonzalez D, Zahringer U, Moreno E, Moriyon I. Brucella abortus and its closest phylogenetic relative, Ochrobactrum spp., differ in outer membrane permeability and cationic peptide resistance. Infect Immun. 2000;68(6):3210-8.
101. Huang L, Krieg AM, Eller N, Scott DE. Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria. Infect Immun. 1999;67(12):6257-63.
102. Kariminia A, Kavoossy G, Khatami S, Zowghi E, Ardestani SK. Study of interleukin-10 and interleukin-12 productions in response to lipopolysaccharides extracted from two different Brucella strains. Comp Immunol Microbiol Infect Dis. 2002;25(2):85-93.
103. Sutterwala FS, Noel GJ, Clynes R, Mosser DM. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med. 1997;185(11):1977-85.
104. Sutterwala FS, Noel GJ, Salgame P, Mosser DM. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med. 1998;188(1):217-22.
105. Gerber JS, Mosser DM. Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J Immunol. 2001;166(11):6861-8.
106. Anderson CF, Gerber JS, Mosser DM. Modulating macrophage function with IgG immune complexes. J Endotoxin Res. 2002;8(6):477-81.
107. Caron E, Gross A, Liautard JP, Dornand J. Brucella species release a specific, protease-sensitive, inhibitor of TNF-alpha expression, active on human macrophage-like cells. J Immunol. 1996;156(8):2885-93.
108. Jubier-Maurin V, Boigegrain RA, Cloeckaert A, Gross A, Alvarez-Martinez MT, Terraza A, Liautard J, Kohler S, Rouot B, Dornand J, Liautard JP. Major outer membrane protein Omp25 of Brucella suis is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages. Infect Immun. 2001;69(8):4823-30.
109. Zhan Y, Liu Z, Cheers C. Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms. Infect Immun. 1996;64(7):2782-6.
110. Murphy EA, Parent M, Sathiyaseelan J, Jiang X, Baldwin CL. Immune control of Brucella abortus 2308 infections in BALB/c mice. FEMS Immunol Med Microbiol. 2001;32(1):85-8.
111. Izadjoo MJ, Polotsky Y, Mense MG, Bhattacharjee AK, Paranavitana CM, Hadfield TL, Hoover DL. Impaired control of Brucella melitensis infection in Rag1-deficient mice. Infect Immun. 2000;68(9):5314-20.
112. Fernandez-Lago L, Rodriguez-Tarazona E, Vizcaino N. Differential secretion of interleukin-12 (IL-12) subunits and heterodimeric IL-12p70 protein by CD-1 mice and murine macrophages in response to intracellular infection by Brucella abortus. J Med Microbiol. 1999;48(12):1065-73.
113. Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance to Brucella abortus infection. Infect Immun. 1995;63(4):1387-90.
114. Sathiyaseelan J, Goenka R, Parent M, Benson RM, Murphy EA, Andrea SF, Baldwin CL. Brucella abortus-susceptible mice turn off an initial vigorous type 1 immune response: rescue by IL-12. Cell Immunol. In press 2006.
115. Ko J, Gendron-Fitzpatrick A, Ficht TA, Splitter GA. Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice. Infect Immun. 2002;70(12):7004-12.
116. Pasquali P, Adone R, Gasbarre LC, Pistoia C, Ciuchini F. Effect of exogenous interleukin-18 (IL-18) and IL-12 in the course of Brucella abortus 2308 infection in mice. Clin Diagn Lab Immunol. 2002;9(2):491-2.
117. Aste-Amezaga M, Ma X, Sartori A, Trinchieri G. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol. 1998;160(12):5936-44.
118. Wu C, Warrier RR, Wang X, Presky DH, Gately MK. Regulation of interleukin-12 receptor beta1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells. Eur J Immunol. 1997;27(1):147-54.
119. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today. 1991;12(3):A49-A53.
120. Fernandes DM, Baldwin CL. Interleukin-10 downregulates protective immunity to Brucella abortus. Infect Immun. 1995;63(3):1130-3.
121. Hort GM, Weisenburger J, Borsdorf B, Peters C, Banai M, Hahn H, Jacob J, Mielke ME. Delayed type hypersensitivity-associated disruption of splenic periarteriolar lymphatic sheaths coincides with temporary loss of IFN-gamma production and impaired eradication of bacteria in Brucella abortus-infected mice. Microbes Infect. 2003;5(2):95-106.
122. Bosseray N, Plommet M, De Rycke J. Development of Brucella abortus, Brucella melitensis and Brucella suis infection in mice to a chronic stage and cure. Ann Rech Vet. 1982;13(2):153-61.
123. Morfitt DC, Cheville NF, Jensen AE. Dimunition of virulence of B. abortus for severe combined immunodeficient mice. Proc Conf Res Workers Animal Dis. 1991;2(2).
124. Fernandez-Lago L, Monte M, Chordi A. Endogenous gamma interferon and interleukin-10 in Brucella abortus 2308 infection in mice. FEMS Immunol Med Microbiol. 1996;15(2-3):109-14.
125. Zhan Y, Cheers C. Endogenous gamma interferon mediates resistance to Brucella abortus infection. Infect Immun. 1993;61(11):4899-901.
126. Stevens MG, Pugh GW Jr, Tabatabai LB. Effects of gamma interferon and indomethacin in preventing Brucella abortus infections in mice. Infect Immun. 1992;60(10):4407-9.
127. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science. 2003;302(5645):654-9.
128. Dunn PL, North RJ. Early gamma interferon production by natural killer cells is important in defense against murine listeriosis. Infect Immun. 1991;59(9):2892-900.
129. Fernandes DM, Benson R, Baldwin CL. Lack of a role for natural killer cells in early control of Brucella abortus 2308 infections in mice. Infect Immun. 1995;63(10):4029-33.
130. Salmeron I, Rodriguez-Zapata M, Salmeron O, Manzano L, Vaquer S, Alvarez-Mon M. Impaired activity of natural killer cells in patients with acute brucellosis. Clin Infect Dis. 1992;15(5):764-70.
131. Dornand J, Lafont V, Oliaro J, Terraza A, Castaneda-Roldan E, Liautard JP. Impairment of intramacrophagic Brucella suis multiplication by human natural killer cells through a contact-dependent mechanism. Infect Immun. 2004;72(4):2303-11.
132. Murphy E, Robertson GT, Parent M, Hagius SD, Roop RM, Elzer PH, Baldwin CL. Major histocompatibility complex class I and II expression on macrophages containing a virulent strain of Brucella abortus measured using green fluorescent protein-expressing brucellae and flow cytometry. FEMS Immunol Med Microbiol. 2002;33(3):191-200.
133. Svetic A, Jian YC, Lu P, Finkelman FD, Gause WC. Brucella abortus induces a novel cytokine gene expression pattern characterized by elevated IL-10 and IFN-gamma in CD4+ T cells. Int Immunol. 1993;5(8):877-83.
134. Weynants V, Walravens K, Didembourg C, Flanagan P, Godfroid J, Letesson JJ. Quantitative assessment by flow cytometry of T-lymphocytes producing antigen-specific gamma-interferon in Brucella immune cattle. Vet Immunol Immunopathol. 1998;66(3-4):309-20.
135. Pavlov H, Hogarth M, McKenzie IF, Cheers C. In vivo and in vitro effects of monoclonal antibody to Ly antigens on immunity to infection. Cell Immunol. 1982;71(1):127-38.
136. Oliveira SC, Splitter GA. CD8+ type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. Eur J Immunol. 1995;25(9):2551-7.
137. He Y, Vemulapalli R, Zeytun A, Schurig GG. Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51. Infect Immun. 2001;69(9):5502-8.
138. Myers L, Croft M, Kwon BS, Mittler RS, Vella AT. Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J Immunol. 2005;174(12):7625-32.
139. Inoue S, Golding B, Scott D. Programming of CTL with heat-killed Brucella abortus and antigen allows soluble antigen alone to generate effective secondary CTL. Vaccine. 2005;23(14):1730-8.
140. Agranovich I, Scott DE, Terle D, Lee K, Golding B. Down-regulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathway. Infect Immun. 1999;67(9):4418-26.
141. Splitter GA, Everlith KM. Brucella abortus regulates bovine macrophage-T-cell interaction by major histocompatibility complex class II and interleukin-1 expression. Infect Immun. 1989;57(4):1151-7.
142. Forestier C, Deleuil F, Lapaque N, Moreno E, Gorvel JP. Brucella abortus lipopolysaccharide in murine peritoneal macrophages acts as a down-regulator of T cell activation. J Immunol. 2000;165(9):5202-10.
143. Lapaque N, Takeuchi O, Corrales F, Akira S, Moriyon I, Howard JC, Gorvel JP. Differential inductions of TNF-alpha and IGTP, IIGP by structurally diverse classic and non-classic lipopolysaccharides. Cell Microbiol. 2006;8(3):401-13.
144. Lapaque N, Forquet F, de Chastellier C, Mishal Z, Jolly G, Moreno E, Heuser JE, He HT, Gorvel JP. Characterization of Brucella abortus lipopolysaccharide macrodomains as mega rafts. Cell Microbiol. 2006;8(2):197-206.
145. Bertotto A, Gerli R, Spinozzi F, Muscat C, Scalise F, Castellucci G, Sposito M, Candio F, Vaccaro R. Lymphocytes bearing the gamma delta T cell receptor in acute Brucella melitensis infection. Eur J Immunol. 1993;23(5):1177-80.
146. Oliaro J, Dudal S, Liautard J, Andrault JB, Liautard JP, Lafont V. Vgamma9Vdelta2 T cells use a combination of mechanisms to limit the spread of the pathogenic bacteria Brucella. J Leukoc Biol. 2005;77(5):652-60.
147. Montaraz JA, Winter AJ, Hunter DM, Sowa BA, Wu AM, Adams LG. Protection against Brucella abortus in mice with O-polysaccharide-specific monoclonal antibodies. Infect Immun. 1986;51(3):961-3.
148. Betts M, Beining P, Brunswick M, Inman J, Angus RD, Hoffman T, Golding B. Lipopolysaccharide from Brucella abortus behaves as a T-cell-independent type 1 carrier in murine antigen-specific antibody responses. Infect Immun. 1993;61(5):1722-9.
149. Elzer PH, Jacobson RH, Nielsen KH, Douglas JT, Winter AJ. BALB/c mice infected with Brucella abortus express protracted polyclonal responses of both IgG2a and IgG3 isotypes. Immunol Lett. 1994;42(3):145-50.
150. Winter AJ, Duncan JR, Santisteban CG, Douglas JT, Adams LG. Capacity of passively administered antibody to prevent establishment of Brucella abortus infection in mice. Infect Immun. 1989;57(11):3438-44.
151. Bellaire BH, Roop RM, Cardelli JA. Opsonized virulent Brucella abortus replicates within nonacidic, endoplasmic reticulum-negative, LAMP-1-positive phagosomes in human monocytes. Infect Immun. 2005;73(6):3702-13.
152. Fernandez-Prada CM, Nikolich M, Vemulapalli R, Sriranganathan N, Boyle SM, Schurig GG, Hadfield TL, Hoover DL. Deletion of wboA enhances activation of the lectin pathway of complement in Brucella abortus and Brucella melitensis. Infect Immun. 2001;69(7):4407-16.
153. Corbeil LB, Blau K, Inzana TJ, Nielsen KH, Jacobson RH, Corbeil RR, Winter AJ. Killing of Brucella abortus by bovine serum. Infect Immun. 1988;56(12):3251-61.
154. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol. 2001;166(12):7381-8.
155. Gray CA, Lawrence RA. A role for antibody and Fc receptor in the clearance of Brugia malayi microfilariae. Eur J Immunol. 2002;32(4):1114-20.
156. Rivera J, Zaragoza O, Casadevall A. Antibody-mediated protection against cryptococcus neoformans pulmonary infection is dependent on B cells. Infect Immun. 2005;73(2):1141-50.
157. Moore T, Ananaba GA, Bolier J, Bowers S, Belay T, Eko FO, Igietseme JU. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology. 2002;105(2):213-21.
158. Bosio CM, Gardner D, Elkins KL. Infection of B cell-deficient mice with CDC 1551, a clinical isolate of Mycobacterium tuberculosis: delay in dissemination and development of lung pathology. J Immunol. 2000;164(12):6417- 25.
159. Kima PE, Constant SL, Hannum L, Colmenares M, Lee KS, Haberman AM, Shlomchik MJ, McMahon-Pratt D. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous Leishmaniasis. J Exp Med. 2000;191(6):1063-8.
160. Colmenares M, Constant SL, Kima PE, McMahon-Pratt D. Leishmania pifanoi pathogenesis: selective lack of a local cutaneous response in the absence of circulating antibody. Infect Immun. 2002;70(12):6597-605.
161. Miles SA, Conrad SM, Alves RG, Jeronimo SM, Mosser DM. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med. 2005;201(5):747-54.
162. Buxbaum LU, Scott P. Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions. Infect Immun. 2005;73(4):2101-8.
163. Padigel UM, Farrell JP. Control of infection with Leishmania major in susceptible BALB/c mice lacking the common gamma-chain for FcR is associated with reduced production of IL-10 and TGF-beta by parasitized cells. J Immunol. 2005;174(10):6340-5.
164. Brown DR, Reiner SL. Polarized helper-T-cell responses against Leishmania major in the absence of B cells. Infect Immun. 1999;67(1):266-70.
165. Virgin HW, Unanue ER. Suppression of the immune response to Listeria monocytogenes. I. Immune complexes inhibit resistance. J Immunol. 1984;133(1):104-9.
166. Virgin HW, Unanue ER. Immune complexes suppress cellular immunity. Ann N Y Acad Sci. 1984;437:16-27.
167. Tripp CS, Beckerman KP, Unanue ER. Immune complexes inhibit antimicrobial responses through interleukin-10 production. Effects in severe combined immunodeficient mice during Listeria infection. J Clin Invest. 1995;95(4):1628-34.
168. Virgin HW, Wittenberg GF, Unanue ER. Immune complex effects on murine macrophages. I. Immune complexes suppress interferon-gamma induction of Ia expression. J Immunol. 1985;135(6):3735-43.
169. Grazia CM, Sutterwala FS, Trinchieri G, Mosser DM, Ma X. Suppression of IL-12 transcription in macrophages following Fc gamma receptor ligation. J Immunol. 2001;166(7):4498-506.
170. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in Leishmaniasis. J Immunol. 2001;166(2):1141-7.
171. Pecanha LM, Snapper CM, Lees A, Yamaguchi H, Mond JJ. IL-10 inhibits T cell-independent but not T cell-dependent responses in vitro. J Immunol. 1993;150(8):3215-23.
172. te Velde AA, de Waal MR, Huijbens RJ, de Vries JE, Figdor CG. IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J Immunol. 1992;149(12):4048-52.
173. Barnes N, Gavin AL, Tan PS, Mottram P, Koentgen F, Hogarth PM. FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity. 2002;16(3):379-89.
174. Gavin AL, Barnes N, Dijstelbloem HM, Hogarth PM. Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J Immunol. 1998;160(1):20-3.
175. Yuan R, Clynes R, Oh J, Ravetch JV, Scharff MD. Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses. J Exp Med. 1998;187(4):641-8.
176. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 2005;23(1):41-51.
177. Sakamoto N, Shibuya K, Shimizu Y, Yotsumoto K, Miyabayashi T, Sakano S, Tsuji T, Nakayama E, Nakauchi H, Shibuya A. A novel Fc receptor for IgA and IgM is expressed on both hematopoietic and non-hematopoietic tissues. Eur J Immunol. 2001;31(5):1310-6.
178. Shibuya A, Sakamoto N, Shimizu Y, Shibuya K, Osawa M, Hiroyama T, Eyre HJ, Sutherland GR, Endo Y, Fujita T, Miyabayashi T, Sakano S, Tsuji T, Nakayama E, Phillips JH, Lanier LL, Nakauchi H. Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. Nat Immunol. 2000;1(5):441-6.
179. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76(3):519-29.
180. Gavin AL, Hamilton JA, Hogarth PM. Extracellular mutations of non-obese diabetic mouse Fcgamma RI modify surface expression and ligand binding. J Biol Chem. 1996;271(29):17091-9.
181. Fossati-Jimack L, Ioan-Facsinay A, Reininger L, Chicheportiche Y, Watanabe N, Saito T, Hofhuis FMA, Gessner JE, Schiller C, Schmidt RE, Honjo T, Verbeek JS, Izui S. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III. J Exp Med. 2000;191(8):1293-302.
182. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677-86.
183. Olsson S, Sundler R. The role of lipid rafts in LPS-induced signaling in a macrophage cell line. Mol Immunol. 2006;43(6):607-12.